Roche's drug is the first cancer immunotherapy to be approved by the FDA for adjuvant treatment of NSCLC ... and patients a new way to treat early lung cancer that has the potential to ...
Do patients with early-stage non–small cell lung cancer (NSCLC ... with resectable NSCLC benefit from immunotherapy in both the neoadjuvant and adjuvant settings, the advisory panel did not ...
Active specific immunotherapy; BCG: Bacille Calmette–Guérin; KLH: Keyhole limpet hemocyanin; MPL: Monophosphoryl lipid A; NSCLC: Non-small-cell lung cancer. Various adjuvant products are ...
Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...
The efficacy of immunotherapy against triple-negative breast cancer (TNBC) heavily relies on intratumoral infiltration of ...
News Medical on MSN7d
Study reveals how bile acids impact immunotherapy in liver cancerImmunotherapy is a modern approach to cancer treatment that uses a patient's own immune system to help fight tumors.
Cancer is now the second leading cause of death worldwide, and rates are climbing-especially in younger adults. Breast, ...
The positive trial results could help Regeneron cushion the blow of its disappointing fourth-quarter sales for Eylea, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback